The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
Contact health care provider if severe/persistent GI symptoms develop or if changes in vision occur during therapy
CrossRef A Novel Index Using Soluble CD36 Is Associated with the Prevalence of Type 2 Diabetes Mellitus: Comparison Study with Triglyceride-Glucose Index Ho Jin Kim, Jun Sung Moon, Il Rae Park, Joong Hee Kim, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee Endocrinology and Metabolism.2017
Wirth, F
The age-related decline in copper peptide availability creates a deficiency state that compromises the skin's regenerative capacity and accelerates the appearance of fine lines, wrinkles, and structural deterioration
10.1016/j.regpep.2014.05.001 [DOI] [PubMed] [Google Scholar] David D
